全球微生物 API 市場：按宿主、類型、最終用戶和地區分類

Global Microbial API Market, By Host, By Type, By End User, By Region

出版日期: 2025年03月27日 | 出版商:

Coherent Market Insights | 英文 165 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

預計 2025 年全球微生物 API 市場規模為 696.9 億美元，到 2032 年將達到 1,097.3 億美元，2025 年至 2032 年的年複合成長率為 6.7%。

報告範圍		報告詳細資訊
基準年	2024	2025年的市場規模	696.9億美元
效能數據	從2020年到2024年	預測期	2025年至2032年
預測期：2025-2032年年複合成長率：	6.70%	2032年價值預測	1097.3億美元

微生物API是指利用各種微生物（例如細菌、真菌和酵母）透過微生物發酵產生的治療物質或活性藥物成分。微生物API主要分為兩類：小分子API和大分子API。小分子原料藥是通常透過化學合成生產的小型治療物質。大分子原料藥，通常稱為生技藥品，是透過重組DNA技術或受控微生物發酵生產的複雜治療物質，例如單株抗體、疫苗、血液因子等。

大分子微生物API相較於小分子原料藥具有一定優勢。其高標靶特異性和低毒性使其對癌症、糖尿病等慢性疾病有更佳的治療效果。此外，利用活微生物生產大分子微生物製劑的工藝，使其能夠靈活地生產各種個人化醫療產品。

市場動態：

全球微生物API市場受學名藥藥和生物相似藥需求成長的驅動，這源自於成本效益的提升。此外，微生物發酵在反應特異性、生產率和產量方面均優於化學合成，促使製藥商加強對微生物API生產的投資。然而，建立、開發和擴大大分子微生物API生產流程的資本要求高，該製程複雜且資本密集，嚴格的監管流程預計將成為限制市場成長的一些因素。

創新發酵技術的開發有助於降低生產成本，為微生物API製造商提供了豐厚的機會。此外，作為生物製品，如果生產過程缺乏嚴格的品管，它們容易產生雜質和批次間不一致。這導致大分子量微生物API面臨更高的監管門檻和更高的產品成本。

從地區來看，北美由於醫療成本高且醫療服務便捷而佔據市場主導地位。然而，亞太地區是成長最快的市場，主要由中國和印度等國家推動。這一成長歸因於經濟成長、可支配收入的增加、醫療基礎設施的擴張以及對生技藥品需求的不斷成長。

本研究的主要特點

本報告對全球微生物 API 市場進行了詳細分析，並提供了預測期 2025-2032 的市場規模和年複合成長率（CAGR%）（假設 2024 年為基準年）。
它揭示了各個領域的潛在商機，並解釋了該市場的有吸引力的投資提案矩陣。
它還提供了有關市場促進因素、限制因素、機會、新產品發布和核准、市場趨勢、區域前景和主要企業採用的競爭策略的重要見解。
全球微生物 API 市場的主要企業是根據公司亮點、產品系列、關鍵亮點、財務績效和策略等參數進行的分析。
本報告的見解將使負責人和公司經營團隊能夠就未來的產品發布、類型升級、市場擴張和行銷策略做出明智的決策。
全球微生物 API 市場報告迎合了該行業的各個相關人員，例如投資者、供應商、產品製造商、經銷商、新進入者和金融分析師。
相關人員可以透過用於分析全球微生物 API 市場的各種策略矩陣來促進決策。

Report Coverage	Report Details
Base Year:	2024	Market Size in 2025:	USD 69.69 Bn
Historical Data for:	2020 To 2024	Forecast Period:	2025 To 2032
Forecast Period 2025 to 2032 CAGR:	6.70%	2032 Value Projection:	USD 109.73 Bn

Microbial APIs refer to therapeutic substances or active pharmaceutical ingredients produced through microbial fermentation using various microorganisms such as bacteria, fungi, or yeast. There are mainly two types of microbial APIs: small molecule APIs and large molecule APIs. Small molecule APIs are low-molecular-weight therapeutic substances that are usually produced through chemical synthesis. Large molecule APIs, commonly known as biologics, are complex therapeutic substances like monoclonal antibodies, vaccines, blood factors, etc. that are produced by recombinant DNA technology or controlled microbial fermentation.

Large molecule microbial APIs have certain advantages over small molecule APIs. Due to their high target specificity and lower toxicity, they provide better treatment outcomes for chronic diseases like cancer, diabetes, etc. The manufacturing process of large molecule microbial APIs using living microbes also allows for flexible production of a wide range of product variants catering to personalized medicine.

Market Dynamics:

The global microbial API market is driven by the rising demand for generic and biosimilar drugs owing to cost efficiency. Moreover, microbial fermentation offers advantages over chemical synthesis in terms of reaction specificity, productivity, and yields, which is encouraging pharmaceutical manufacturers to increase investment in microbial API production. However, the high capital requirement for setting up microbial fermentation facilities, developing, and scaling up the manufacturing process of large molecule microbial APIs is complex and capital-intensive and stringent regulatory processes are some of the factors expected to restrain market growth.

The development of innovative fermentation technologies to decrease production costs presents lucrative opportunities for microbial API manufacturers. Additionally, being biological products, they are more prone to impurities and batch-to-batch inconsistencies if not manufactured under stringent quality controls. This raises regulatory hurdles and the cost of goods for large molecule microbial APIs.

Among regions, North America dominates the market due to high healthcare expenditures and better access to care. However, Asia Pacific is poised to be the fastest-growing market arena, led by countries like China and India. This growth can be attributed to growing economies, rising disposable incomes, expanding medical infrastructure, and increasing demand for biologics.

Key features of the study:

This report provides in-depth analysis of the global microbial API market, and provides market size (US$ Bn) and compound annual growth rate (CAGR%) for the forecast period 2025-2032, considering 2024 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global microbial API market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include Merck & Co., Inc., Topfond Pharmaceutical Co., Ltd., DSM, CSPC Pharmaceutical Group Limited., KOLON LIFE SCIENCE, Teva Pharmaceutical Industries Ltd., Lonza, Akums Lifesciences Ltd., AbbVie Inc., Xellia Pharmaceuticals, BASF, Dr. Reddy's Laboratories and Lupin
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global microbial API market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global microbial API market

Detailed Segmentation:

Global Microbial API Market

By Host
- Mammalian
- Bacterial
- Fungal
By Type
- Antibody
- Peptide
- Protein
- Small Molecule
- Vaccine
By Site
- In-house
- Outsourced
By End User
- Pharmaceutical Companies
- Biopharmaceutical Companies
- Others
By Region
- North America
- Latin America
- Europe
- Asia Pacific
- Middle East
- Africa
Company Profiles
- Merck & Co., Inc.
- Topfond Pharmaceutical Co., Ltd.
- DSM
- CSPC Pharmaceutical Group Limited.
- KOLON LIFE SCIENCE
- Teva Pharmaceutical Industries Ltd.
- Lonza
- Akums Lifesciences Ltd.
- AbbVie Inc.
- Xellia Pharmaceuticals
- BASF
- Reddy's Laboratories
- Lupin

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Top 3 Market Findings
- Top 3 Market Opportunity

3. Key Industry Insights

Market Dynamics
Drivers
Restraints
Opportunities
Impact Analysis
Pest Analysis
Porters Analysis
Technological Advancement
Merger, Acquisition and Collaboration Scenario
Recent Product Approvals/Launches
Company Market Share Analysis

4. Global Microbial API Market, By Host, 2020 - 2032 ( US$ Billion)

Introduction
- Market Size and Forecast, 2020 - 2032, ( US$ Billion)
- Segment Trends
Mammalian, 2020 - 2032( US$ Billion)
- Introduction
- Market Size and Forecast, 2020 - 2032, ( US$ Billion)
Bacterial, 2020 - 2032( US$ Billion)
- Introduction
- Market Size and Forecast, 2020 - 2032, ( US$ Billion)
Fungal, 2020 - 2032( US$ Billion)
- Introduction
- Market Size and Forecast, 2020 - 2032, ( US$ Billion)

5. Global Microbial API Market, By Type, 2020 - 2032 ( US$ Billion)

Introduction
- Market Size and Forecast, 2020 - 2032, ( US$ Billion)
- Segment Trends
Antibody, 2020 - 2032( US$ Billion)
- Introduction
- Market Size and Forecast, 2020 - 2032, ( US$ Billion)
Peptide, 2020 - 2032( US$ Billion)
- Introduction
- Market Size and Forecast, 2020 - 2032, ( US$ Billion)
Protein, 2020 - 2032( US$ Billion)
- Introduction
- Market Size and Forecast, 2020 - 2032, ( US$ Billion)
Small Molecule, 2020 - 2032( US$ Billion)
- Introduction
- Market Size and Forecast, 2020 - 2032, ( US$ Billion)
Vaccine, 2020 - 2032( US$ Billion)
- Introduction
- Market Size and Forecast, 2020 - 2032, ( US$ Billion)

6. Global Microbial API Market, By Site, 2020 - 2032 ( US$ Billion)

Introduction
- Market Size and Forecast, 2020 - 2032, ( US$ Billion)
- Segment Trends
In-house, 2020 - 2032( US$ Billion)
- Introduction
- Market Size and Forecast, 2020 - 2032, ( US$ Billion)
Outsourced, 2020 - 2032( US$ Billion)
- Introduction
- Market Size and Forecast, 2020 - 2032, ( US$ Billion)

7. Global Microbial API Market, By End user, 2020-2032, (US$ Bn)

Introduction
- Market Size and Forecast, 2020 - 2032, ( US$ Billion)
- Segment Trends
Pharmaceutical Companies, 2020 - 2032( US$ Billion)
- Introduction
- Market Size and Forecast, 2020 - 2032, ( US$ Billion)
Biopharmaceutical Companies, 2020 - 2032( US$ Billion)
- Introduction
- Market Size and Forecast, 2020 - 2032, ( US$ Billion)
Others, 2020 - 2032( US$ Billion)
- Introduction
- Market Size and Forecast, 2020 - 2032, ( US$ Billion)

8. Global Microbial API Market, By Molecule, 2020 - 2032 ( US$ Billion)

Introduction
- Market Size and Forecast, 2020 - 2032, ( US$ Billion)
- Segment Trends
Innovative, 2020 - 2032( US$ Billion)
- Introduction
- Market Size and Forecast, 2020 - 2032, ( US$ Billion)
Generic, 2020 - 2032( US$ Billion)
- Introduction
- Market Size and Forecast, 2020 - 2032, ( US$ Billion)

9. Global Microbial API Market, By Region, 2020-2032, (US$ Bn)

Introduction
- Market Share Analysis, 2020 - 2032, ( US$ Billion)
- Segment Trends
By Region
- Introduction
- Market Size and Forecast, 2020 - 2032, ( US$ Billion)
North America
- Introduction
- Market Size and Forecast, By Host, 2020 - 2032, ( US$ Billion)
- Market Size and Forecast, By Type, 2020 - 2032, ( US$ Billion)
- Market Size and Forecast, By Site, 2020 - 2032, ( US$ Billion)
- Market Size and Forecast, By End-use, 2020 - 2032, ( US$ Billion)
- Market Size and Forecast, By Molecule, 2020 - 2032, ( US$ Billion)
- Market Size and Forecast, By Country, 2020 - 2032, ( US$ Billion)
  - U.S.
- Introduction
- Market Size and Forecast, 2020 - 2032, ( US$ Billion)
Canada
- Introduction
- Market Size and Forecast, 2020 - 2032, ( US$ Billion)
Europe
- Introduction
- Market Size and Forecast, By Host, 2020 - 2032, ( US$ Billion)
- Market Size and Forecast, By Type, 2020 - 2032, ( US$ Billion)
- Market Size and Forecast, By Site, 2020 - 2032, ( US$ Billion)
- Market Size and Forecast, By End-use, 2020 - 2032, ( US$ Billion)
- Market Size and Forecast, By Molecule, 2020 - 2032, ( US$ Billion)
- Market Size and Forecast, By Country, 2020 - 2032, ( US$ Billion)
  - U.K
- Introduction
- Market Size and Forecast, 2020 - 2032, ( US$ Billion)
Germany
- Introduction
- Market Size and Forecast, 2020 - 2032, ( US$ Billion)
France
- Introduction
- Market Size and Forecast, 2020 - 2032, ( US$ Billion)
Italy
- Introduction
- Market Size and Forecast, 2020 - 2032, ( US$ Billion)
Spain
- Introduction
- Market Size and Forecast, 2020 - 2032, ( US$ Billion)
Russia
- Introduction
- Market Size and Forecast, 2020 - 2032, ( US$ Billion)
Rest of Europe
- Introduction
- Market Size and Forecast, 2020 - 2032, ( US$ Billion)
Asia Pacific
- Introduction
- Market Size and Forecast, By Host, 2020 - 2032, ( US$ Billion)
- Market Size and Forecast, By Type, 2020 - 2032, ( US$ Billion)
- Market Size and Forecast, By Site, 2020 - 2032, ( US$ Billion)
- Market Size and Forecast, By End-use, 2020 - 2032, ( US$ Billion)
- Market Size and Forecast, By Molecule, 2020 - 2032, ( US$ Billion)
- Market Size and Forecast, By Country, 2020 - 2032, ( US$ Billion)
  - China
- Introduction
- Market Size and Forecast, 2020 - 2032, ( US$ Billion)
India
- Introduction
- Market Size and Forecast, 2020 - 2032, ( US$ Billion)
Japan
- Introduction
- Market Size and Forecast, 2020 - 2032, ( US$ Billion)
Australia
- Introduction
- Market Size and Forecast, 2020 - 2032, ( US$ Billion)
South Korea
- Introduction
- Market Size and Forecast, 2020 - 2032, ( US$ Billion)
ASEAN
- Introduction
- Market Size and Forecast, 2020 - 2032, ( US$ Billion)
Rest of Asia Pacific
- Introduction
- Market Size and Forecast, 2020 - 2032, ( US$ Billion)
Latin America
- Introduction
- Market Size and Forecast, By Host, 2020 - 2032, ( US$ Billion)
- Market Size and Forecast, By Type, 2020 - 2032, ( US$ Billion)
- Market Size and Forecast, By Site, 2020 - 2032, ( US$ Billion)
- Market Size and Forecast, By End-use, 2020 - 2032, ( US$ Billion)
- Market Size and Forecast, By Molecule, 2020 - 2032, ( US$ Billion)
- Market Size and Forecast, By Country, 2020 - 2032, ( US$ Billion)
  - Brazil
- Introduction
- Market Size and Forecast, 2020 - 2032, ( US$ Billion)
Mexico
- Introduction
- Market Size and Forecast, 2020 - 2032, ( US$ Billion)
Argentina
- Introduction
- Market Size and Forecast, 2020 - 2032, ( US$ Billion)
Rest of Latin America
- Introduction
- Market Size and Forecast, 2020 - 2032, ( US$ Billion)
Middle East
- Introduction
- Market Size and Forecast, By Host, 2020 - 2032, ( US$ Billion)
- Market Size and Forecast, By Type, 2020 - 2032, ( US$ Billion)
- Market Size and Forecast, By Site, 2020 - 2032, ( US$ Billion)
- Market Size and Forecast, By End-use, 2020 - 2032, ( US$ Billion)
- Market Size and Forecast, By Molecule, 2020 - 2032, ( US$ Billion)
- Market Size and Forecast, By Country, 2020 - 2032, ( US$ Billion)
  - GCC
- Introduction
- Market Size and Forecast, 2020 - 2032, ( US$ Billion)
Israel
- Introduction
- Market Size and Forecast, 2020 - 2032, ( US$ Billion)
Rest of Middle East
- Introduction
- Market Size and Forecast, 2020 - 2032, ( US$ Billion)
Africa
- Introduction
- Market Size and Forecast, By Host, 2020 - 2032, ( US$ Billion)
- Market Size and Forecast, By Type, 2020 - 2032, ( US$ Billion)
- Market Size and Forecast, By Site, 2020 - 2032, ( US$ Billion)
- Market Size and Forecast, By End-use, 2020 - 2032, ( US$ Billion)
- Market Size and Forecast, By Country, 2020 - 2032, ( US$ Billion)
  - North Africa
- Introduction
- Market Size and Forecast, 2020 - 2032, ( US$ Billion)
Central Africa
- Introduction
- Market Size and Forecast, 2020 - 2032, ( US$ Billion)
South Africa
- Introduction
- Market Size and Forecast, 2020 - 2032, ( US$ Billion)

10. Company Profiles - Microbial API Market

KOLON LIFE SCIENCE
- Company Overview
- Product/Service Portfolio
- Financial Performance
- Recent Developments/Updates
- Strategic Overview
Shandong Lukang Pharmaceutical Co., Ltd.
Teva Pharmaceutical Industries Ltd.
Lonza
Merck & Co., Inc.
Topfond Pharmaceutical Co., Ltd.
DSM
CSPC Pharmaceutical Group Limited